Risk factors

Quince Therapeutics (QNCX) risk factors

Item 1A of every Quince Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open QNCX in Gloom →
Quince Therapeutics' chart, financials and news, free in your browser.Open QNCX in Gloom →
  • FY2025 10-K risk factors
    50 risks19 new44 dropped14 reworded

    The company discontinued development after NEAT results and is now focused on strategic alternatives, including a possible reverse merger.

    Filed Apr 10, 2026
  • FY2024 10-K risk factors
    75 risks

    Quince Therapeutics depends entirely on the clinical and commercial success of its lead drug candidate, eDSP, for A-T.

    Filed Mar 24, 2025